---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-059424"
form_type: "8-K"
ticker: "TMDX"
cik: "0001756262"
company_name: "TransMedics Group, Inc."
filed_at: "2023-11-06T23:59:59+00:00"
generated_at: "2026-06-08T21:16:54.956841+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# TransMedics Q3 revenue $66.4M (+159% YoY); raises FY2023 guidance to $222-230M

## Summary
- Revenue $66.4M, up 159% YoY; includes $2.1M from new aviation business and $1.6M non-recurring charter revenue.
- Net loss widened to $25.4M from $7.4M, driven by $29.2M non-recurring acquisition costs including $27.2M in-process R&D charge.
- Gross margin 61% vs 71% a year ago, impacted by Summit Aviation transition and legacy charter exit costs.
- Cash $427.1M as of Sep 30; full-year 2023 revenue guidance raised to $222-230M from prior $180-190M.
- Summit Aviation acquisition closed, adding aviation service to organ transplant logistics offering.

## SEC filing metadata
- accession: 0000950170-23-059424
- form_type: 8-K
- ticker: TMDX
- cik: 0001756262
- company_name: TransMedics Group, Inc.
- filed_at: 2023-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1756262/000095017023059424/0000950170-23-059424-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1756262/000095017023059424/tmdx-20231106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-059424
- JSON: https://secwatch.observer/filing/0000950170-23-059424.json
- Plain text: https://secwatch.observer/filing/0000950170-23-059424.txt

## Key facts
- Earnings Releases
  TransMedics Group, Inc. reported quarter ended September 30, 2023 results: revenue $66.4 million. Guidance raised.
  - Period: quarter ended September 30, 2023
  - Revenue: $66.4 million
  - Guidance: raised
  - Result: reported results
  source text: therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended September 30, 2023. Recent Highlights ▪ Net revenue of $66.4 million in the third quarter of 2023, a 159% increase compared to the third quarter of 2022, including $1.6 million non-recurring charter revenue ▪ Closed acquisition of Summit Aviation,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1756262/000095017023059424/0000950170-23-059424-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.